LDLR and metabolic dysfunction-associated steatohepatitis: Along the same vein, Cmpd 81 and lovastatin alone comparably reduce hepatic cholesterol synthesis in MFMC-fed or WD-fed Ldlr−/− mice, and Cmpd 81 synergizes with lovastatin to further decrease lipid levels (Fig. 6e and Supplementary Fig. 7g), indicating that induced degradation of HMGCR may bring therapeutic benefit to treat NASH.